In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel

Journal of Controlled Release

Volumn 103, Issue 1, 2005, Pages 7-19

  Konishi, Mitsunaga ^a,b   Tabata, Yasuhiko ^b   Kariya, Masatoshi ^a   Hosseinkhani, Hossein ^b   Suzuki, Ayako ^a   Fukuhara, Ken ^a   Mandai, Masaki ^a   Takakura, Kenji ^a   Fujii, Shingo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Adriamycin; Anti tumor effect; CDDP; Dual release; Gelatin hydrogel

Indexed keywords

ALDEHYDES; BIOCHEMISTRY; BIODEGRADATION; BLOOD; CELLS; CONCENTRATION (PROCESS); CROSSLINKING; DRUG PRODUCTS; HYDROGELS; PHOSPHATES; SOLUTIONS; TISSUE;

ADRIAMYCIN (ADM); CISPLATIN (CDDP); GELATIN; TUMOR CELLS;

TUMORS;

CISPLATIN; DOXORUBICIN; GELATIN; GLUTARALDEHYDE; PHOSPHATE BUFFERED SALINE; WATER;

AIR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; ASSAY; BIODEGRADABILITY; BLOOD CHEMISTRY; CANCER INHIBITION; CANCER SURVIVAL; CANCER TISSUE; CHEMICAL PROCEDURES; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS LINKING; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; DRUG RELEASE; DRUG RETENTION; DRUG SCREENING; DRUG TISSUE LEVEL; FEMALE; FREEZE DRYING; HYDROGEL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; SUSTAINED DRUG RELEASE; TEMPERATURE; TIME; TUMOR CELL; WATER CONTENT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOTRANSFORMATION; CISPLATIN; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GELATIN; HYDROGELS; MICE; MICE, INBRED BALB C; TUMOR CELLS, CULTURED;

EID: 13844293985     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.11.014     Document Type: Article

References (42)

1. M. Harries, and M. Gore Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis Lancet Oncol. 3 2002 529 536
2. S.A. Hundahl Surgical quality in trials of adjuvant cancer therapy J. Surg. Oncol. 80 2002 177 180
3. M. Markman Intraperitoneal chemotherapy Crit. Rev. Oncol./Hematol. 31 1999 239 246
4. Y. Nagata, N. Araki, H. Kimura, K. Fujiwara, K. Okajima, T. Aoki, M. Mitsumori, K. Sasai, M. Hiraoka, T. Higuchi, and S. Fujii Neoadjuvant chemotherapy by transcatheter arterial infusion method for uterine cancer JVIR 11 2000 313 319
5. S. Ning, N. Yu, D.M. Brown, S. Kanekal, and S.J. Knox Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system Radiother. Oncol. 50 1999 215 223
6. H. Idani, J. Matsuoka, T. Yasuda, K. Kobayashi, and N. Tanaka Intra-tumoral injection of doxorubicin (Adriamycin) encapsulated in liposome inhibits tumor growth, prolongs survival time and is not associated with local or systemic side effects Int. J. Cancer 88 2000 645 651
7. K.A. Walter, R.J. Tamargo, A. Olivi, P.C. Burger, and H. Brem Intratumoral chemotherapy Neurosurgery 37 1995 1128 1145
8. S. Voulgaris, M. Partheni, M. Karamouzis, P. Dimopoulos, N. Papadakis, and H.P. Kalofonos Intratumoral doxorubicin in patients with malignant brain gliomas Am. J. Clin. Oncol (CCT) 25 2002 60 64
9. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and EPR effect in macromolecular therapeutics: a review J. Control. Release 65 2000 271 284
10. Y. Mizumura, Y. Matsumura, T. Hamaguchi, N. Nishiyama, K. Kataoka, T. Kawaguchi, W.J. Hrushesky, F. Moriyasu, and T. Kakizoe Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity, while maintaining antitumor activity Jpn. J. Cancer Res. 92 3 2001 328 336
11. K. Itoi, C.-Y. Tabata, O. Ike, Y. Shimizu, M. Kuwabara, M. Kyo, S.H. Hyon, and Y. Ikada In vivo suppressive effects of copoly(glycolic/l-lactic acid)microspheres containing CDDP on murine tumor cells J. Control. Release 42 1996 175 184
12. K. Tokuda, S. Natsugoe, M. Shimada, T. Kumanohoso, M. Baba, S. Takao, K. Nakamura, K. Yamada, H. Yosizawa, Y. Hatate, and T. Aikou Design and testing of a new cisplatin form using a base material by combining poly-d,l-lactic acid and polyethylene glycol acid against peritoneal metastasis Int. J. Cancer 76 1998 709 712
13. E. Harper, W. Dang, R.G. Lapidus, and R.I. Garver Jr. Enhanced efficacy of a novel controlled release Paclitaxel formulation (PACLIMER Delivery System) for local-regional therapy of lung cancer tumor nodules in mice Clin. Cancer Res. 5 1999 4242 4248
14. M. Konishi, Y. Tabata, M. Kariya, A. Suzuki, M. Mandai, K. Nanbu, K. Takakura, and S. Fujii In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel J. Control. Release 92 2003 301 313
15. D.F. Emerich, P. Snodgrass, D. Lafrerniere, R.L. Dean, H. Salzberg, J. Marsh, B. Perdomo, M. Arastu, S.R. Winn, and R.T. Bartus Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusion Pharm. Res. 19 2002 1052 1060
16. D.F. Emerich, S.R. Winn, Y. Hu, J. Marsh, P. Snodgrass, D. Lafreniere, S.T. Wien, B.P. Hasler, and R.T. Bartus Injectable chemotherapeutic microspheres and glioma: I. Enhanced survival follow implantation into the cavity wall of debulked tumors Pharm. Res. 17 2000 776 781
17. N. Nishiyama, S. Okazaki, H. Cabral, M. Miyamoto, Y. Kato, Y. Sugiyama, Y. Matsumura, and K. Kataoka Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice Cancer Res. 63 2003 8977 8983
18. H. Okino, R. Maeyama, T. Manabe, T. Matsuda, and M. Tanaka Trans-tissue, sustained release of gemicitabine from photocured gelatin gel inhibits the growth of heterotopic human pancreatic tumor in nude mice Clin. Cancer Res. 15 2003 5786 5793
19. H. Yamada, N. Uchida, R. Maekawa, and T. Yoshioka Sequence-dependent anti-tumor efficacy of combination chemotherapy with nedaplatin, a newly developed platinum, and paclitaxel Cancer Lett. 172 2001 17 25
20. Y. Tabata, and Y. Ikada Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities Biomaterials 20 1999 2169 2175
21. P.J. Flory Swelling of network structure Principles of Polymer Chemistry 1953 Cornell University Press New York 576 581
22. Y. Tabata, S. Hijikata, and Y. Ikada Enhanced vascularization and tissue granulation by basic fibroblast growth factor impregnated in gelatin hydrogels J. Control. Release 31 1994 189 199
23. S. Zeng, Y.Z. Chen, L. Fu, K.R Johnson, and W. Fan In vitro evaluation of schedule dependent interactions between docetaxcel and doxorubicin against human breast and ovarian cancer cells Clin. Cancer Res. 6 2000 3766 3773
24. N. Murashima, A. Gochi, M. Kenmotsu, K. Hamazaki, M. Funaki, S. Ohtsuka, and N. Tanaka Schedule dependent combined sensitivity testing of anti-cancer agents in human gastric carcinoma cell lines J. Int. Med. Res. 29 2001 189 197
25. N. Kohno, T. Ohnuma, M. Kaneko, and J.F. Holland Interactions of doxorubicin and cis-platin in squamous cell carcinoma cells in culture Br. J. Cancer 58 1988 330 334
26. Y. Tabata, A. Nagano, and Y. Ikada Biodegradation of hydrogel carrier incorporating fibroblast growth factor Tissue Eng. 5 2 1999 127 138
27. Y. Ikada, and Y. Tabata Protein release from gelatin matrices Adv. Drug Deliv. Rev. 31 1998 287 301
28. Y. Tabata, K. Yamada, L. Hong, S. Miyamoto, and Y. Ikada Skull bone regeneration in primates in response to basic fibroblast growth factor J. Neurosurg. 91 1999 851 856
29. Y. Kimura, M. Ozeki, T. Inamoto, and Y. Tabata Time course of de novo adipogenesis in matrigel by gelatin microspheres incorporating basic fibroblast growth factor Tissue Eng. 8 2000 603 613
30. M. Ozeki, and Y. Tabata Promoted growth of murine hair follicles through controlled release of basic fibroblast growth factor Tissue Eng. 8 2002 359 366
31. Y. Fukunaka, K. Iwanaga, K. Morimoto, M. Kakemi, and Y. Tabata Controlled release of plasmid DNA from cationaized gelatin hydrogels based on hydrogel degradation J. Control. Release 80 2002 333 343
32. M. Yamamoto, Y. Ikada, and Y. Tabata Controlled release of growth factors based on biodegradation of gelatin hydrogel J. Biomater. Sci., Polym. Ed. 12 2001 77 88
33. T. Imai, K. Fujii, S. Shiraishi, and M. Odagiri Alteration of pharmacokinetics and nephrotoxicity of cisplatin by alginates J. Pharm. Sci. 86 1997 244 247
34. K.H. Bouhadir, E. Alsberg, and D.J. Mooney Hydrogels for combination delivery of antineoplastic agents Biomaterials 22 2001 2625 2633
35. H. Fan, and A.K. Dash Effect of cross-linking on the in vitro release kinetics of doxorubicin from gelatin implants Int. J. Pharm. 213 2001 103 116
36. E. Leo, M.A. Vandelli, R. Cameroni, and F. Forni Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: involvement of the drug in the cross-linking process Int. J. Pharm. 155 1997 75 82
37. N. Kurihara, T. Kubota, Y. Hoshiya, Y. Otani, M. Watanabe, K. Kumai, and M. Kitajima Antitumor activity of cis-diamminedichloroplatinum (II) against human tumor xenografts depends on its area under the curve in nude mice J. Surg. Oncol. 61 1996 138 142
38. J.H. Zheng, C.T. Chen, J.L.S. Au, and M.G. Wientjes Time- and concentration-dependent penetration of doxorubicin in prostate tumors AAPS PharmSci 3 2001 1 9
39. A.E. Bogden, J.P. Moreau, and P.A. Eden Proliferative response of human and animal tumours to surgical wounding of normal tissues: onset, duration and inhibition Br. J. Cancer 75 1997 1021 1027
40. C.R. Rossi, S. Mocellin, P. Pilati, M. Foletto, L. Quintieri, P. Palatini, and M. Lise Pharmacokinetics of intraperitoneal cisplatin and doxorubicin Surg. Oncol. Clin. N. Am. 12 2003 781 794
41. C.R. Rossi, M. Deraco, M.D. Simone, S. Mocellin, P. Pilati, M. Foletto, F. Cavaliere, S. Kusamura, A. Gronchi, and M. Lise Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: clinical outcome and prognostic factors in 60 consecutive patients Cancer 100 2004 1943 1950
42. T.P. Richardson, M.C. Peters, and D.J. Mooney Polymeric system for dual growth factor delivery Nat. Biotechnol. 19 2001 1029 1034